ARNA Arena Pharmaceuticals Inc

Price (delayed)

$64.79

Market cap

$3.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.4

Enterprise value

$3.54B

Sector: Healthcare
Industry: Biotechnology

Highlights

The quick ratio has increased by 27% year-on-year and by 21% since the previous quarter
ARNA's equity is up by 10% YoY
The gross profit has plunged by 99% YoY and by 82% from the previous quarter
The revenue has dropped by 99% year-on-year and by 82% since the previous quarter

Key stats

What are the main financial stats of ARNA
Market
Shares outstanding
60.7M
Market cap
$3.93B
Enterprise value
$3.54B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.6
Price to sales (P/S)
67,949.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62,177.44
Earnings
Revenue
$57,000
EBIT
-$418.51M
EBITDA
-$414.63M
Free cash flow
-$379.42M
Per share
EPS
-$7.4
Free cash flow per share
-$6.35
Book value per share
$18
Revenue per share
$0
TBVPS
$19.8
Balance sheet
Total assets
$1.18B
Total liabilities
$97.94M
Debt
$44.59M
Equity
$1.09B
Working capital
$1.07B
Liquidity
Debt to equity
0.04
Current ratio
23.61
Quick ratio
22.92
Net debt/EBITDA
0.94
Margins
EBITDA margin
-727,419.3%
Gross margin
100%
Net margin
-742,007%
Operating margin
-796,349.1%
Efficiency
Return on assets
-33.9%
Return on equity
-36.9%
Return on invested capital
-50.5%
Return on capital employed
-36.8%
Return on sales
-734,229.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARNA stock price

How has the Arena Pharmaceuticals stock price performed over time
Intraday
2.73%
1 week
-5.6%
1 month
-2.26%
1 year
29.97%
YTD
-15.67%
QTD
-6.63%

Financial performance

How have Arena Pharmaceuticals's revenue and profit performed over time
Revenue
$57,000
Gross profit
$57,000
Operating income
-$453.92M
Net income
-$422.94M
Gross margin
100%
Net margin
-742,007%
The gross profit has plunged by 99% YoY and by 82% from the previous quarter
The revenue has dropped by 99% year-on-year and by 82% since the previous quarter
The operating income has declined by 31% year-on-year and by 6% since the previous quarter
Arena Pharmaceuticals's net income has decreased by 31% YoY and by 4.5% from the previous quarter

Growth

What is Arena Pharmaceuticals's growth rate over time

Valuation

What is Arena Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.6
P/S
67,949.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62,177.44
The EPS has decreased by 14% YoY
The P/B is 69% less than the 5-year quarterly average of 11.8
ARNA's equity is up by 10% YoY
The revenue has dropped by 99% year-on-year and by 82% since the previous quarter

Efficiency

How efficient is Arena Pharmaceuticals business performance
ARNA's return on invested capital has dropped by 60% year-on-year and by 9% since the previous quarter
ARNA's ROE is down by 26% YoY and by 2.2% from the previous quarter
ARNA's ROA is down by 26% year-on-year and by 2.4% since the previous quarter

Dividends

What is ARNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARNA.

Financial health

How did Arena Pharmaceuticals financials performed over time
The quick ratio has increased by 27% year-on-year and by 21% since the previous quarter
ARNA's current ratio is up by 26% YoY and by 20% from the previous quarter
ARNA's debt is 96% less than its equity
The debt to equity has declined by 20% year-on-year
ARNA's equity is up by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.